MedTrace Logo

Local Study of Akatinol Memantine in VaD in Russia

NCT03986424 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2022-07-22

No results posted yet for this study

Summary

The study evaluates the clinical efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs. Akatinol Memantine 10 mg (double-doses) in patients suffering from moderate and moderately severe vascular dementia.

Conditions

  • Vascular Dementia

Interventions

DRUG

Akatinol Memantine 20 mg

Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day

DRUG

Akatinol Memantine 10 mg

Akatinol Memantine 10 mg to be taken orally, twice daily

Sponsors & Collaborators

  • LLC Merz Pharma, Russia

    collaborator UNKNOWN

  • Merz Pharmaceuticals GmbH

    lead INDUSTRY

Principal Investigators

  • Merz Russia Medical Expert · Merz Russia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-23
Primary Completion
2022-06-01
Completion
2022-06-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03986424 on ClinicalTrials.gov